Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (December 2024)

51 slides from Clearside Biomedical's investor presentation, Dec 12, 2024

  1. Slide 1: Investor Presentation December 2024

    Investor Presentation December 2024 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: Delivering on the Potential of the Suprachoroidal Space

    Delivering on the Potential of the Suprachoroidal Space Proven Leader in Suprachoroidal Delivery with Thousands of Injections Performed in the Clinic Validated Suprachoroidal Space (SCS) Delivery with Approved Product, Multiple Collaborations, and Comprehensive IP Portfolio Differentiated SCS Clinic

  4. Slide 4: Promising Pipeline Using Clearside's Suprachoroidal Injection Platform

    Promising Pipeline Using Clearside’s Suprachoroidal Injection Platform 1XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb. 2In licensed territories, Arctic Vision is responsible for clinical dev

  5. Slide 5: Multiple Validating Partnerships Expand Utilization of SCS Microinjector Technology

    Multiple Validating Partnerships Expand Utilization of SCS Microinjector® Technology 1XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb. 2In China, Arctic Vision is responsible for clinical deve

  6. Slide 6: Core Competencies in Delivery & Formulation Drive Patented Technology

    Core Competencies in Delivery & Formulation Drive Patented Technology DRUG PATENTS Administration of a variety of drugs to the suprachoroidal space by microinjection DISEASE PATENTS Methods of treating ocular disorders by SCS administration KEY INTELLECTUAL PROPERTY COMPONENTS Comprehensive IP portf

  7. Slide 7: Proven Commercial Capabilities in Suprachoroidal Delivery

    Proven Commercial Capabilities in Suprachoroidal Delivery Proprietary Microinjector with Significant Clinical Experience ISO Certified Commercial Scale Injector Manufacturing Capability Formulation Expertise Experience in Navigating the Drug/Device Regulatory Pathway 1st FDA Product Approved for SCS

  8. Slide 8: Suprachoroidal Delivery via SCS Microinjector

    Suprachoroidal Delivery via SCS Microinjector®

  9. Slide 9: Delivering on the Potential of the Suprachoroidal Space: A Novel Approach to Drug Delivery

    Delivering on the Potential of the Suprachoroidal Space (SCS®): A Novel Approach to Drug Delivery Into the Back of the Eye

  10. Slide 10: Benefits for Patients and Physicians Using SCS Microinjector Delivery

    Benefits for Patients and Physicians Using SCS Microinjector® Delivery Enhanced Safety Much lower risk of endophthalmitis as direct contact to immune system vs intravitreal injection Injectate Flows to Back of the Eye Reduced risk of floaters, snow globe effect, or other visual disturbances No Impla

  11. Slide 11: SCS Microinjector: Drug/Device Combination with Proven Versatility

    Abbreviations: UME = uveitic macular edema; DME = diabetic macular edema; DR = diabetic retinopathy; Sources: Clearside data on file | 1Kurup, et. al, Macula Society 2021 Safety of the Suprachoroidal Injection Procedure Utilizing SCS Microinjector® across Three Retinal Disorders. SCS Microinjector®:

  12. Slide 12: Straightforward Suprachoroidal Injection Technique

    Straightforward Suprachoroidal Injection Technique Hold the microinjector perpendicular to the ocular surface Ensure firm contact with sclera by maintaining a dimple throughout injection Inject slowly over 5 – 10 seconds Perpendicular Dimple Slow Source: Clearside July 24, 2024 KOL Webinar

  13. Slide 13: Clearside Needle Size Equivalent to Most Commonly Used Intravitreal Injections

    Clearside Needle Size Equivalent to Most Commonly Used Intravitreal Injections and Smaller than Other TKIs in development 22G 25G 30G Outer Diameter of the Needle Relative to the Ocular Tissue Inner Diameter of the Needle Drug Product Passage 30G needle results in less damage to the ocular tissue wo

  14. Slide 14: CLS-AX (axitinib injectable suspension)

    CLS-AX (axitinib injectable suspension) New mechanism of action with potential for longer duration of effect for the treatment of wet AMD

  15. Slide 15: Axitinib is a Highly Potent, Highly Selective Pan-VEGF Inhibitor

    Axitinib is a Highly Potent, Highly Selective Pan-VEGF Inhibitor Inhibits ALL VEGF Receptors (VEGFR-1, VEGFR-2, VEGFR-3) Intrinsic pan-VEGF inhibition through receptor blockade More active than anti-VEGF-A in in-vitro angiogenesis model1-2 Approved AMD treatments are focused VEGF-A inhibitors Tyrosi

  16. Slide 16: Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery

    Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery Axitinib High potency TKI with pan-VEGF receptor inhibition Proprietary CLS-AX Small Molecule Suspension Formulation Clearside formulation expertise Delivery via SCS Microinjector® Utilizes the same administration device as F

  17. Slide 17: A Large and Growing Market Opportunity

    A large and growing market opportunity Age-Related Macular Degeneration (AMD) is a Multi-Billion Dollar Market Sources: 1 Pennington, Katie L and DeAngelis, Margaret M, Eye and Vision, Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lip

  18. Slide 18: Positioning CLS-AX for Real-World Success

    Positioning CLS-AX for Real-World Success *Dosing regimens are per respective product labels | EYLEA® and EYLEA HD® are registered trademarks of Regeneron Pharmaceuticals| LUCENTIS® and VABYSMO® are registered trademarks of Genentech/Roche Maintain Vision & Reduce Office Visits Objective is to maint

  19. Slide 19: Phase 2b Topline Data Summary and Phase Plans

    Phase 2b Topline Data Summary and Phase 3 Plans 19

  20. Slide 20: CLS-AX Now Phase Ready Based on Positive ODYSSEY Data in Wet AMD

    CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data in Wet AMD Enrolled Only Difficult-to-Treat Participants with Active Disease Achieved Primary Outcome Maintaining Stable BCVA with Repeat Dosing Compelling Intervention-Free Rates Abbreviation: Wet AMD = neovascular age-related macular degenera

  21. Slide 21: ODYSSEY Phase 2b Clinical Trial

    ODYSSEY Phase 2b Clinical Trial Trial Objectives: Evaluate safety, efficacy & duration of CLS-AX in participants with wet AMD Primary Outcomes: Mean change in BCVA from Baseline to Week 36; Safety & tolerability Secondary Outcomes: Other changes in visual function and retinal imaging, including CST;

  22. Slide 22: ODYSSEY Trial Design and Dosing Regimen

    * Disease Activity Assessments (DAA): Conducted at Week 12 through 32 to determine need for supplemental treatment. # In CLS-AX arm, following 3 loading doses of aflibercept and initial dose of CLS-AX at Baseline, participants will receive CLS-AX at least every 24 weeks unless more frequently requir

  23. Slide 23: Demographics and Baseline Characteristics

    Demographics and Baseline Characteristics Characteristics CLS-AX Aflibercept Overall No. of participants 40 20 60 Mean age (range), years 76.9 (51-90) 80.3 (54-96) 78.0 (51-96) Women, no. (%) 25 (62.5) 14 (70.0) 39 (65.0) Race, no. (%) White Asian 37 (92.5) 3 (7.5) 20 (100) 0 57 (95.0) 3 (5.0) Media

  24. Slide 24: CLS-AX Demonstrated Positive Clinical Activity in Wet AMD

    CLS-AX Demonstrated Positive Clinical Activity in Wet AMD Abbreviations: CST=Central Subfield Thickness Injection frequency reduction calculated by the average number of treatments 24 Weeks prior to Screening Visit as compared to Average number of treatments up to 24 Weeks after Baseline Visit. Over

  25. Slide 25: Intervention-Free Rates By Week Up to Each Visit

    Intervention–Free Rates By Week Up to Each Visit Two-Thirds of Participants Dosed with CLS-AX Reached Six Months Without Additional Treatment Calculation accounts for missed treatments; time of initial administration of study drug shown as month 0 on figure. Intervention-free rate calculation: if pa

  26. Slide 26: Weeks Before and After CLS-AX Consistently Reduced the Frequency of Injections

    24 Weeks Before and After CLS-AX Consistently Reduced the Frequency of Injections Comparison of Wet AMD Treatments Pre- and Post- Randomization Injection post Baseline includes re-dosing with CLS-AX and/or supplementary treatment with aflibercept. Injection frequency reduction calculated by the aver

  27. Slide 27: Stable Best Corrected Visual Acuity (BCVA) Over Weeks

    Stable Best Corrected Visual Acuity (BCVA) Over 36 Weeks ^Study drug administration for aflibercept participants given at Weeks 12, 20 and 28. Abbreviations: BCVA = best corrected visual acuity; SEM = standard error of the mean. P-value based on a 2-sample t-test between treatment groups . BCVA With

  28. Slide 28: Stable Central Subfield Retinal Thickness (CSRT) Over Weeks

    Stable Central Subfield Retinal Thickness (CSRT) Over 36 Weeks as Verified by Independent Reading Center ^Study drug administration for aflibercept participants given at Weeks 12, 20 and 28. Abbreviations: CSRT = central subfield retinal thickness – as reported by the reading center; SEM = standard

  29. Slide 29: CLS-AX Demonstrated A Positive Safety Profile

    CLS-AX Demonstrated A Positive Safety Profile Safety Profile Well-tolerated safety profile through 36 weeks including after mandatory re-dosing of CLS-AX at Week 24 No Serious Adverse Events (SAEs) No ocular SAEs or treatment-related SAEs: No drug or procedure related ocular SAEs No reported drug or

  30. Slide 30: CLS-AX Now Phase Ready Based on Positive ODYSSEY Data

    CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data ✔︎ ✔︎ ✔︎ ✔︎ Achieved Primary Objective: Stable BCVA to Week 36 Difficult-to-treat Wet AMD participants with confirmed activity Compelling injection free rates up to 6 months Injection frequency reduced by nearly 84% Positive safety profile No o

  31. Slide 31: CLS-AX Phase Program Current Plans

    CLS-AX Phase 3 Program Current Plans

  32. Slide 32: Phase Program Summary

    Phase 3 Program Summary Two pivotal, non-inferiority trials Two arms with ~225 participants per arm: CLS-AX 1mg vs aflibercept 2mg Similar to Phase 3 trial design of EYLEA HD and VABYSMO in maintenance phase Phase 3 flexible dosing data will be differentiated from other TKI programs End-of-Phase 2 M

  33. Slide 33: CLS-AX Phase 3 Non-Inferiority Study Design in Wet AMD

    Target patient population: Treatment naïve No more than 1 previous injection of anti-VEGF Two strategies to reduce variability to enhance success in non-inferiority trial: At Screening Participants must have 20/80 to 20/32 AND CST <500 at diagnosis Minimizes enrollment of highly variable participant

  34. Slide 34: Flexible Dosing to Support Commercial Success

    Personalized Treatment Interval (PTI) assessment enables physicians to use “real world” approach with flexible dosing schedule based on participant needs Flexible Dosing to Support Commercial Success Re-Dosing Criteria with CLS-AX Improve consistency in assessing need for re-dosing by using OCT biom

  35. Slide 35: Study Designed to Maximize Commercial and Competitive Potential in Wet AMD

    Year 1 Study Designed to Maximize Commercial and Competitive Potential in Wet AMD A, Aflibercept 2mg; C, CLS-AX 1 mg; S, Sham injection; R/BL, Randomization/Baseline; PE, Primary Endpoint; EC, Exclusion Criteria; PTI, Personalized Treatment Interval assessment by AI tool: IRF and/or SRF changes from

  36. Slide 36: Study Design Intended to Provide Additional Safety and Efficacy Data After Primary Endpoint

    After 36-Week Primary Endpoint: Aflibercept arm moves to CLS-AX every 16 weeks (q16w) To maintain masking To collect more safety data To collect efficacy data for q16w CLS-AX in year 2 CLS-AX arm stays on the original assignment after PTI assessment Allows readjustment of dosing in CLS-AX arm (close

  37. Slide 37: Year 2 Evaluation After Primary Endpoint

    Year 2 Evaluation After Primary Endpoint C, CLS-AX 1 mg; S, Sham injection; EOS, End of Study. For masking purposes, PTI assessments will be performed in all participants at all visits starting at Week 40. Week 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 Visit 16 17 18 19 20 21 22 23 24 25 26 27 28

  38. Slide 38: Pipeline Expansion Opportunity in Geographic Atrophy

    Pipeline Expansion Opportunity in Geographic Atrophy

  39. Slide 39: Potential Target Product Profile Aligns with SCS Suspension or SCS Gene Therapy

    Potential Target Product Profile (TPP) Aligns with SCS Suspension or SCS Gene Therapy Potential Advantages of Suprachoroidal Delivery in Geographic Atrophy Less invasive, in-office procedure Systemic therapy may be effective, but potential infection risks in this elderly population Local ocular ther

  40. Slide 40: Pathology of Age-Related Macular Degeneration (AMD)

    Pathology of Age-Related Macular Degeneration (AMD) Wong JHC et al., Front Neurosci 16: 1009599

  41. Slide 41: Choroidal Hypoxia Theory and Choriocapillaris are Damaged First

    Choroidal Hypoxia Theory and Choriocapillaris are Damaged First Geographic Atrophy is a Choroidal Disease Choriocapillaris endothelial cells damage with ghost vessels before any significant RPE changes Choriocapillaris (CC) vascular density is significantly lower in GA donor No meaningful difference

  42. Slide 42: Small Molecule Can Access the Diseased Area of the RPE and Choroid

    Larger molecules cannot get through Bruch’s membrane So, if given intravitreally, it can only treat the RPE side Aging intensifies disease actions and even peptides might not be able to get through Small Molecule Can Access the Diseased Area of the RPE and Choroid Images modified from Hammadi et al

  43. Slide 43: A Differentiated and Promising Approach Focusing on Choroidal Health

    Neuroprotection Promising preclinical evidence Limited clinical success Lipid pathway Complex lipid metabolism pathways Clinical effectiveness likely to require removal of lipid from Bruch’s Extracellular matrix modulation (HTRA1, TIMP3 & MMPs) Molecular mechanism is not controversial Anti-HTRA1 fai

  44. Slide 44: Summary

    Summary <a ° cree jee . . a a ee ee ee oe | ee ereee

  45. Slide 45: Innovative and Experienced Leader in Suprachoroidal Drug Delivery

    Innovative and Experienced Leader in Suprachoroidal Drug Delivery First Approved SCS Product XIPERE Versatile In multiple indications & clinical trials CLS-AX via SCS Targeting large Wet AMD Market Robust Safety Profile No endophthalmitis SCS Drug Delivery Platform Upcoming Potential Catalysts CLS-A

  46. Slide 46: TM

    Nasdaq: CLSD TM

  47. Slide 47: ones Jee . . Lecce s ests ce ee

    ones Jee . . Lecce s ests ce ee

  48. Slide 48: ODYSSEY Trial Focused on Participants with Active Disease

    ODYSSEY Trial Focused on Participants with Active Disease Criteria for Supplemental Treatment Dosing Regimen Key Inclusion Criteria Disease Activity Assessments (DAA) Diagnosed with neovascular AMD (wet AMD) within 36 months of screening History of 2 to 4 anti-VEGF treatments in 6 months before scre

  49. Slide 49: ODYSSEY Trial Enrolled Rapidly

    ODYSSEY Trial Enrolled Rapidly Study Activity Date First Participant Randomized July 12, 2023 Last Participant Randomized December 13, 2023 SITES ACTIVATED PARTICIPANTS SCREENED PARTICIPANTS RANDOMIZED 32 60 158 Disposition CLS-AX Aflibercept Overall Enrolled, n 158 Randomized, n 40 20 60 Completed,

  50. Slide 50: Intervention-Free Rates By Week Up to Each Visit

    Intervention–Free Rates By Week Up to Each Visit Two-Thirds of Participants Dosed with CLS-AX Reached 6 Months Without Supplemental Therapy 1Calculation accounts for missed visits or assessments; Time of initial administration of study drug shown as month 0 on figure. Intervention-free rate calculat

  51. Slide 51: ODYSSEY Confirmed the Ability to Administer Multiple Doses of CLS-AX

    ODYSSEY Confirmed the Ability to Administer Multiple Doses of CLS-AX with a Well-Tolerated Safety Profile Multi-Dosing Data CLS-AX Doses Received Including Baseline # Doses # Participants % of total enrolled (n=40) 1 2 5% 2 32 80% 3 6 15% Of the 40 participants in the trial on study drug: 32 receive

Clearside Biomedical — Investor Presentation (December 2024) on 6ix